Alto Neuroscience

Study shows the power of electroencephalography and machine learning to help predict response to psychotherapy (or lack thereof) in patients with PTSD

by Leave a Comment

A fas­ci­nat­ing study just pub­lished in Nature Men­tal Health aimed at help­ing pre­dict the out­comes of psy­chother­a­py for patients with Post-Trau­mat­ic Stress Dis­or­der (PTSD) using Machine Learn­ing (ML) and elec­troen­cephalog­ra­phy (EEG) data.

PTSD is a men­tal health con­di­tion trig­gered by expe­ri­enc­ing or wit­ness­ing a trau­mat­ic event; two evi­dence-based treatments–Prolonged Expo­sure (PE) and Cog­ni­tive Pro­cess­ing Ther­a­py (CPT)–are com­mon­ly used to help patients, with var­ied results.

In this study, the researchers used a super­vised machine learn­ing approach and high-den­si­ty rest­ing-state EEG (rsEEG) record­ings to pre­dict indi­vid­ual psy­chother­a­py out­comes. They iden­ti­fied a pre­treat­ment EEG con­nec­tiv­i­ty sig­na­ture in the eyes-open theta fre­quen­cy range that was pre­dic­tive of patients’ respons­es to both PE and CPT. [Read more…] about Study shows the pow­er of elec­troen­cephalog­ra­phy and machine learn­ing to help pre­dict response to psy­chother­a­py (or lack there­of) in patients with PTSD

BrainHealth Week starts today! Plus: dancing, personalized mental health, brain stimulation and more

by

Wel­come to a new edi­tion of Sharp­Brains e‑newsletter, annouc­ing the kick-off of Brain­Health Week and fea­tur­ing some stim­u­lat­ing resources and teasers.

#1. Brain­Health Week (Feb­ru­ary 20–24th) starts today:

Explore many fun events includ­ing a dai­ly text chal­lenge, a talk with the always great Dr. Tom Insel, and more!

#2. With­out Brain Health, you do not have Health

Impor­tant arti­cle giv­en that “It typ­i­cal­ly takes twen­ty to forty years or more for sci­en­tif­ic dis­cov­er­ies to mean­ing­ful­ly ben­e­fit human life. We can­not wait that long.” — Wise words!

#3. Sin Salud Cere­bral, Ust­ed no tiene Salud –same arti­cle, in Span­ish, for extra men­tal stim­u­la­tion and for sharing 🙂

“En los últi­mos diez años, los neu­ro­ci­en­tifi­cos hemos des­cu­bier­to mucho acer­ca de cómo fun­ciona el cere­bro, cómo mejo­rar la salud y el fun­cionamien­to del cere­bro y la mente a lo largo de la vida, y cómo esto con­tribuye a nues­tra salud y bien­es­tar en gen­er­al. Únase a nosotros y asegúrese de que los mejores años de su cere­bro están aún por venir, recor­dan­do que: Sin salud cere­bral, ust­ed no tiene salud.”

#4. Ball­room danc­ing can reduce aging-relat­ed brain atro­phy in the hip­pocam­pus (and, more than tread­mill walking!)

“(Danc­ing) gen­er­at­ed sig­nif­i­cant­ly greater improve­ments than tread­mill walk­ing on one mea­sure of exec­u­tive func­tion and on pro­cess­ing speed, which is the time it takes to respond to or process infor­ma­tion. Com­pared with walk­ing, danc­ing was also asso­ci­at­ed with reduced brain atro­phy in the hip­pocam­pus – a brain region that is key to mem­o­ry func­tion­ing and is par­tic­u­lar­ly affect­ed by Alzheimer’s dis­ease … We think that social danc­ing may be more ben­e­fi­cial than walk­ing because it is phys­i­cal­ly, social­ly and cog­ni­tive­ly demand­ing – and there­fore strength­ens a wide net­work of brain regions.”

#5. Alto Neu­ro­science rais­es $60M (equi­ty + cred­it) to help fix the “tri­al and error” approach to psy­chi­atric medication

“To do so, Alto is pair­ing a trove of data on EEG activ­i­ty, genet­ics, behav­ioral task mea­sure­ments and oth­er fac­tors to see which of its drugs fits best with patients who have depres­sion, post-trau­mat­ic stress dis­or­der and oth­er men­tal health con­di­tions. The company’s arti­fi­cial intel­li­gence plat­form homes in on three buck­ets: cog­ni­tion, emo­tion and sleep.”

#6. Voice bio­mark­er plat­form Sonde Health rais­es $19.25M to spread access to men­tal health mon­i­tor­ing and beyond

“GN Group will inte­grate Sonde’s Men­tal Fit­ness vocal bio­mark­er into its hear­ing prod­ucts. The com­pa­ny is already work­ing with Sonde to devel­op an MCI vocal bio­mark­er. Qual­comm, which has already inte­grat­ed Sonde’s vocal bio­mark­ers into its mobile device chipsets, has extend­ed the rela­tion­ship to include its wear­able chipsets.”

#7. The Euro­pean Soci­ety for Brain Stim­u­la­tion oppos­es EU reclas­si­fi­ca­tion of TMS and tDCS, claim­ing a flawed safe­ty assessment

“To put this into per­spec­tive, the like­li­hood of a seizure from rTMS (0.003%) is low­er than that asso­ci­at­ed with the use of anti­de­pres­sants and antipsy­chotics (0.1–1, 5%) … More­over, when such seizures occur they do so most­ly out­side the clinician’s office, by con­trast with rTMS (Per­era et al., 2016). For low inten­si­ty tDCS, tACS, tRNS seizure risk is com­plete­ly absent … As an organ­i­sa­tion and rep­re­sen­ta­tives of NIBS clin­i­cians and pro­fes­sion­als from across Europe, we, the ESBS, there­fore dis­agree with this EU deci­sion and in par­tic­u­lar with the fac­tu­al­ly incor­rect jus­ti­fi­ca­tions of that deci­sion to reclas­si­fy TMS and TES as inva­sive technologies”

Final­ly, a cou­ple of brain teasers to help you test your men­tal rota­tion cog­ni­tive skills:

#8. Can you read a map?

#9. Brain teas­er to stim­u­late your men­tal imagery, spa­tial rota­tion … and appetite

Have a great Brain­Health Week!

Alto Neuroscience raises $60M (equity + credit) to help fix the “trial and error” approach to psychiatric medication

by

Alto Neu­ro­science bags $25M for four Phase II drugs (End­points News):

Anoth­er $25 mil­lion is flow­ing the way of a Cal­i­for­nia biotech attempt­ing to fix the “tri­al and error” sys­tem in neu­ro­science drug R&D.

Alto Neu­ro­science picked up the cap­i­tal from Alpha Wave Ven­tures via an exten­sion to its Series B, bring­ing total equi­ty raised to $100 mil­lion since the startup’s 2019 found­ing. [Read more…] about Alto Neu­ro­science rais­es $60M (equi­ty + cred­it) to help fix the “tri­al and error” approach to psy­chi­atric medication

On cognitive-physical training, brain biomarkers, dementia, ketamine, brain teasers, riddles and more

by

Wel­come to the last 2022 edi­tion of Sharp­Brains e‑newsletter, fea­tur­ing a few select­ed brain health news and fun teasers to chal­lenge your brain and help us all think out­side the box.

#1. “Every­one agrees that Google Glass failed when it came to mar­ket, but to me, it’s a sym­bol of hope … It inspired peo­ple to think beyond tra­di­tion­al ways of mov­ing about our envi­ron­ment. Instead of look­ing down at a device, we could look out at the world and have an over­lay of dig­i­tal infor­ma­tion. It was one of the first steps in physical–digital con­ver­gence that we are see­ing today through­out many indus­tries. And as some­one who has cre­at­ed many inven­tions that nev­er left the lab or were too ear­ly for the mar­ket, I love the fact that Glass came out at all!” — wise words by neu­rotech entre­pre­neur Dr. Cori Lath­an in her new (and excel­lent) book. See Tech­nol­o­gy as a bridge in time: Shap­ing the future of brain health via today’s innovations–including those that “fail”

#2. “Some peo­ple want to do cog­ni­tive train­ing while mov­ing rather than sit­ting down, and that real­ly spoke to me as a pos­si­bil­i­ty for real ben­e­fits giv­en anec­do­tal sto­ries about games like ‘Dance Dance Rev­o­lu­tion.’” — Joaquin A. Anguera, asso­ciate pro­fes­sor at UCSF and direc­tor of Neuroscape‘s Clin­i­cal Divi­sion. See Study: A com­bined cog­ni­tive-phys­i­cal train­ing approach may enhance both mind and body as we age

#3. “Giv­en that ketamine’s rapid action and unex­pect­ed dis­so­cia­tive effects make it a poten­tial­ly worth­while option for treat­ing men­tal health prob­lems, we are on a mis­sion to unpack this mys­tery, at the cross­roads between phar­ma­col­o­gy and neu­ro­science.” See Study iden­ti­fies cog­ni­tive ben­e­fits of ket­a­mine in patients with treat­ment-resis­tant depression

#4. “The grat­i­tude writ­ing group main­tained grat­i­tude lev­els and decreased stress and neg­a­tive affect at one-month post-inter­ven­tion” — that main­te­nance aspect is espe­cial­ly inter­est­ing. See Thanks­giv­ing works: Grat­i­tude jour­nal­ing seen to low­er stress and neg­a­tive cog­ni­tive processes

#5. Impres­sive new funding–especially giv­en mar­ket conditions–with a goal to iden­ti­fy “brain bio­mark­ers by ana­lyz­ing EEG activ­i­ty, behav­ioral task per­for­mance, wear­able data, genet­ics, and oth­er fac­tors to match each patient with the right Alto drug.” See Pre­ci­sion psy­chi­a­try pio­neer Alto Neu­ro­science rais­es $35M to advance dig­i­tal bio­mark­er-to-treat­ment platform

#6. Some bad news. See The FDA ends pre­cer­ti­fi­ca­tion (Pre-Cert) pilot pro­gram, say­ing new author­i­ty required to reg­u­late soft­ware as a med­ical device (SaMD)

#7. And some great news: “(Péter Hudomi­et, study’s lead author) said it’s also pos­si­ble that, giv­en numer­ous stud­ies being released on steps to take to avoid demen­tia, some of the decline may be attrib­uted to peo­ple heed­ing such advice.” See Study finds sharp decrease (near­ly one-third) in the preva­lence of demen­tia among those 65+ in the Unit­ed States

#8. Final­ly, here are a few brain teasers to stim­u­late those neu­rons in your tem­po­ral lobes and to help us all think out­side the box.

 

Have a healthy and won­der­ful 2023!

 

Precision psychiatry pioneer Alto Neuroscience raises $35M to advance digital biomarker-to-treatment platform

by

Alto Neu­ro­science Rais­es $35M Series B Financ­ing (Fins­Mes):

Alto Neu­ro­science, a Los Altos, CA-based neu­ro-tech com­pa­ny which spe­cial­izes in pre­ci­sion psy­chi­a­try, rais­es $35M Series B Financ­ing … The com­pa­ny intends to use the funds to advance lead can­di­dates into Phase 2b stud­ies in major depres­sive dis­or­der … Pro­ceeds from the financ­ing will also be used to progress the company’s arti­fi­cial intel­li­gence-enabled brain bio­mark­er plat­form and launch new clin­i­cal tri­als in areas of high unmet med­ical need. Alto will report Phase 2a data in ear­ly 2023 and fur­ther antic­i­pates Phase 2b data read­outs by ear­ly 2024. [Read more…] about Pre­ci­sion psy­chi­a­try pio­neer Alto Neu­ro­science rais­es $35M to advance dig­i­tal bio­mark­er-to-treat­ment platform